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Abstract
Background: So far, all clinical cases of new variant Creutzfeldt-Jakob disease (vCJD), thought to result from the Bovine
Spongiform Encephalopathy (BSE) prion agent, have shown Methionine–Methionine (M/M) homozygosity at the M129V
polymorphism of the PRNP gene. Although established, this relationship is still not understood. In both vCJD and
experimental BSE models prion agents do reach the bloodstream, raising concerns regarding disease transmission through
blood transfusion.
Methodology/Principal Findings: We investigated the impact of the M129V polymorphism on the expression and
processing of the prion protein in human peripheral blood mononuclear cells (PBMCs) from three blood donor populations
with Methionine-Methionine (M/M), Valine-Valine (V/V) and M/V genotypes. Using real-time PCR, ELISA and immunoblot
assays we were unable to find differences in prion protein expression and processing relating to the M129V polymorphism.
Conclusions/Significance: These results suggest that in PBMCs, the M129V PrP polymorphism has no significant impact on
PrP expression, processing and the apparent glycoform distribution. Prion propagation should be investigated further in
other cell types or tissues.
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Introduction
Transmissible spongiform encephalophathies (TSEs or prion
diseases) are fatal neurodegenerative disorders, of which the main
human form is Creutzfeldt–Jakob disease (CJD) [1,2]. Importantly,
a new variant of CJD (vCJD) has recently emerged [3], believed to
result from oral exposure to Bovine Spongiform Encephalopathy
(BSE). Although the exact nature of the infective agent remains
controversial, many believe that infectivity is closely associated with
theaccumulationofapathologicalmisfoldedprotein,PrP
Sc(Scrapie
Prion Protein), derived from the normal cellular protein PrP
C [4].
PrP
C and PrP
Sc isoforms share the same primary structure [5]: a
single disulfide bond [6], two complex-type N–Linked oligosaccha-
ride chains [7,8], and a C-terminal glycosyl phosphatidylinositol
(GPI) anchor [9]. The difference between the isoforms relates to
their secondary structure: PrP
C is rich in a-helices, while PrP
Sc has a
higher content of b-pleated sheets [10–12]. During prion propaga-
tion, the increase in the level of infectivity is associated in most cases
with the accumulation of the misfolded PrP
Sc protein, believed to
convertPrP
C throughapathologicalconformationalrearrangement
[13]. Although the mechanism explaining this transconformation
remains unclear, two different models have been proposed:
nucleation-polymerization and template-assisted conversion
[14,15]. Both involve the recruitment of normal prion protein
PrP
C. Biochemical studies in cultured cells demonstrate that
conformational rearrangement of PrP
C can occur in the absence
of glycosylation [16] and that N-glycan chains can modulate the in
vitro conversion of PrP
C into PrP
Sc-like molecules [17]. In the
normal brain, PrP
C processing includes proteolysis of the full-length
protein to generate a main N-terminal truncated protein named the
C1 fragment. However, proteolysis can also generate an additional,
longer C-terminus protein –the C2 fragment - that accumulates in
prion-infected brain in particular. [18].The C2 fragment only
accumulates as a resistant truncated protein in CJD-affected brains.
This raises questions about whether this truncated form influences
the possibility of developing the illness. Moreover, studies have
described the accumulation of under-glycosylated, full-length and
N-Terminal truncated PrP as a fingerprint for prion disease [19].
The PRNP gene, on the short arm of human chromosome 20,
encodes the prion protein [20]. Some polymorphisms of the PRNP
open reading frame (ORF) seem to be involved in susceptibility to
different forms of CJD (iCJD, gCJD, sCJD, vCJD) [21]. This is
illustrated by the fact that 100% of the clinical vCJD cases thus far
have been Methionine –Methionine homozygous at the M129V
polymorphism (129-M/M) [22], yet only 40% of the Caucasian
population carry this genotype. Importantly, in classical CJD
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Sc accumulates in neuronal, [23,24] follicular
dendritic cells, and muscle [25], but for vCJD patients, PrP
Sc also
accumulates in lymphoid tissue, including the tonsils and appendix
[26–29]. This distribution raised concerns about blood transfusion
from the very beginning of the epidemic. Since then, studies by
Houston F. et al [30] have demonstrated that prion transmission by
blood transfusion occurs experimentally in sheep infected with
BSE. In humans, three UK vCJD patients had previously been
transfused with red cells donated by individuals who subsequently
developed vCJD 1.5–3.5 years after donation. All three transfu-
sion-recipient patients carried the 129-M/M genotype. A fourth
recipient of red cells from a donor who later developed vCJD, died
from unrelated causes. Post mortem investigation in this case
found abnormal prion accumulation in the spleen and in one
cervical lymph node, but not in the brain [31–33]. Recently, a
person with hemophilia who died of a condition unrelated to
vCJD, only showed evidence of infection with the abnormal prion
protein in the spleen at post mortem. In these cases without clinical
signs, both patients were heterozygous 129-M/V. This bears in
mind the sub-clinical CJD cases with 129-V/V recently described
in a retrospective study of appendix samples [34]. Polymorphism
at position 129 could, therefore, not only influence susceptibility to
prions, but also impact the incubation time or clinical onset of the
disease. One possible mechanism to explain this relation would be
the consequence of 129 polymorphism on PrP
C expression and
processing that are critical for prion propagation [4,16,17,35].
Given the concerns regarding vCJD transmission through blood
transfusion, studying PrP
C in blood seems particularly relevant.
Indeed, PrP
C distribution determined by ELISA and flow
cytometry, shows that plasma mononuclear cells and platelets
express PrP
C, although contradictory results were obtained for red
cells and granulocytes [36,37].
In order to investigate a possible relationship between the
M129V polymorphism and susceptibility to vCJD and PrP
C
expression, we compared three blood donor populations of
different genotypes: M/M, M/V, and V/V at position 129. We
analyzed their expression of total PrP
C (mRNA, protein) and PrP
C
isoforms (glycosylated and truncated proteins) in peripheral blood
mononuclear cells (PBMCs).
Our results showed that in these cells, PrP expression and
processing did not determine susceptibility to prion disease.
Materials and Methods
Blood Samples
After having obtained informed consent in writing from each
blood donor, in compliance with the French law (code de la sante ´
publique article L.1243-3), whole blood was taken in EDTA
collection tubes. Given the well known distribution of codon
M129V genotypes (41% M/M, 49% M/V and 10% V/V) in the
French population, the study did not require the approval of the
Bioethical Review Board. We genotyped a total of 119 donors in
order to obtain a statistically representative V/V population.
Isolation of peripheral blood mononuclear cells (PBMCs)
In order to avoid bias due to physiological variation in the
percentage of granulocytes (40 to 70%) in human blood, we
examined only purified mononuclear cells. Indeed, preliminary
studies performed on leukocyte populations (data not shown)
indicate a lower PrP
C mRNA expression in granulocytes than
mononuclear cells. Consequently, we only purified mononuclear
cells from blood by centrifugation through a Ficoll-Hypaque
gradient (Pharmacia, 91 898 Orsay, France). In brief, whole blood
diluted Vol./Vol. with phosphate-buffer saline (PBS) was carefully
layered upon Ficoll and spun at 700 g. Mononuclear cells were
harvested from the interface of the plasma-platelets layer and the
Ficoll, washed in PBS and suspended in the same buffer. The cell
suspension was analyzed in triplicate, on the ABX (Beckman
Coulter, 95942 Roissy, France) hemocytometer for total cell
number and mononuclear cell purity level. After elimination of
PBS, aliquots of 10
6 PBS-cleared PBMCs were stored at 280uC.
RNA extraction
Total RNA was isolated (High Pure RNA isolation kit, Roche
Diagnostics, 38240 Meylan France) from 10
6 PBMCs, according
to the manufacturer’s instructions. Briefly, cells were lysed by
solubilizing them in lysis/binding buffer optimized for RNA
extraction (4,5M guanidin hydrochloride, 50 mM Tris-HCl and
30% Triton X-100, pH 6.6). Homogenized lysate was then
transferred to a filter tube for binding to the fiberglass filter. After
centrifugation at 10 000 g for 15 sec, residual contaminated DNA
was digested by DNase I (180 U/tube) applied directly to the
fiberglass filter and incubated for 15 min. After washing three
times - in order to eliminate enzymes and cellular impurities -
purified RNA was eluted with 50 ml elution buffer (nuclease-free
sterile water), and immediately stored at 280uC.
As the PRNP ORF sequence is located on only one exon, to
exclude potential contamination by genomic sequences, we treated
total RNA extracts with RNase-free DNase before amplification.
Samples were then controlled for the absence of genomic sequence
by performing PCR directly on the RNA extracts, thus avoiding
the reverse transcription step.
cDNA synthesis
The first cDNA strand was synthesized by reverse transcription
(R.T. at 42uC for 1 hour) from 5 ml of RNA (preheated for 7 min
at 70uC) in the presence of hexanucleotides (7 mM), dNTPs
(800 mM each), 60 U Rnasin Ribonuclease Inhibitor (Promega,
69260 Charbonnie `res France) and 300 U M-MLV-RT (Promega)
in a final volume of 35 ml. cDNA was then purified with ‘‘High
Pure PCR Product Purification Kit’’ (Roche Diagnostics) accord-
ing to the manufacturer’s instructions. The test principle was the
same as previously described for RNA extraction; the only
difference concerned the lysis buffer, which was adapted for
DNA products. Finally, cDNA was eluted with 50 ml elution
buffer, supplemented with salmon sperm DNA (10 ng/ml final),
and kept at 220uC.
Real-time PCR
Standard curve preparation. First, RNA was produced by
in vitro transcription with AmpliScribe T7, T3 and SP6 High Yield
Transcription Kit (Epicentre/Tebu 78610 Le Perray-en-Yvelines
France) according to the manufacturer’s instructions. The ORF
sequence (759 pb) of the human prion gene - inserted into a
pcDNA3 plasmid - was used as the reaction template. Second, four
one-in-ten serial dilutions were prepared from a stock RNA
solution at 10
211 grams/ml (g/ml). This yielded a standard curve
with concentrations ranging from 10
212 to 10
215 g/ml,
corresponding to 2.33610
6 and 2.33610
3copies/reaction.
Primer Sequences. Primer Sequences selected for real-time
PCR were those described by Dodelet et al. [38]. They ensure
amplification of a fragment of 432 pb length, encompassing the
M129V polymorphism within the human prion ORF.
Quantification. Quantification was carried out on a
LightCycler by real-time PCR and SYBR Green I dye (Roche
Diagnostics, Penzberg, Germany). Amplification assays were
performed with 1 ml of cDNA in 20 ml final reaction mixture
containing 2 ml LightCycler-FastStart DNA Master SYBR Green
Codon 129 Genotypes and Blood
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99 and reverse, nt 498 to 510). PCR conditions consisted of an
initial denaturation at 95uC for 5 min, and 45 cycles at 95uC for
15 sec, 65uC for 5 sec, 72uC for 15 sec, 89uC for 5 sec. All
samples were analyzed in duplicate. The amount of DNA was
estimated after each PCR cycle by reading fluorescent dye
incorporation (SYBR Green) at 530 nm in the PCR product. At
the end of each run, a DNA melting step was performed and a
fusion curve was recorded to control the homogeneity and
specificity of the amplified DNA.
Analysis of the results. Readings were performed for each
cycle after a fourth segment at 89uC, in order to exclude non-
specific signal interference with the concentration calculation.
Analysis was automatically performed by LightCycler software 4.0
as follows: after PCR completion, LightCycler software calculated
the copy number of target molecules by plotting the logarithm of
fluorescence versus cycle numbers and setting a baseline x-axis.
From each sample, the baseline identified the cycle (crossing point,
Ct) at which the log-linear signal could be distinguished from the
background. Each run was analyzed by setting the noise band just
above the background fluorescence. A value corresponding to
F=0.5 was systematically chosen for comparison between the
runs. Regression of the x-axis crossing point of each standard with
known concentrations defined the standard curve from which
unknown samples were estimated. Specificity was achieved by
plotting a melting curve graph based on the final PCR.
129 codon Genotyping
According to Teupser et al [39] the following probe pair spans
the nucleic acid sequence responsible for the polymorphism: a
detection probe complementary to the 129M allele and 39-labeled
with fluorescein, and the adjoining, anchoring probe 59-labeled
with Red 640. Genotyping assays were carried out in a reaction
mixture containing 10 ml of amplicons and probes, at 2.5
picomoles each per reaction. Assay conditions consisted of initial
denaturation at 95uC for 2 min, followed by hybridization at 42uC
for 2 min and final denaturation by increasing the series to 75uC
at a rate of 0.1uC with continuous reading at 640 nm. Analysis
using LightCycler was performed by creating a melting profile that
defined the melting temperature (Tm) of the hybrid, composed of
the target DNA and the fluorescent probe pair. Tm depends on
the degree of homology between the two strands, which
distinguishes M129V polymorphism. At the end of the reading,
LightCycler software 4 draws a melting curve, by plotting
fluorescence (F) versus temperature (T), which is automatically
converted to melting peaks (-dF/dT).
Preparation of protein lysate and PNGase F-
deglycosylated protein
All samples were prepared from 10
6 PBMCs according to 2
protocols:
Protein lysate preparation only. Cells were dissociated and
incubated on ice for 30 min in a lysis buffer containing 150 mM
NaCl, 0.5% triton X-100, 0.5% sodium deoxycholate and 50 mM
Tris-HCl pH 7.5, and supplemented with a protease inhibitor
cocktail (Roche, 82372 Penzberg Germany). After centrifugation
at 450 g for 2 min, the supernatant was harvested, added to 46
loading buffer (Invitrogen, Paisley, UK), heated at 95uC for 5 min
and stored at 280uC.
Protein lysate preparation with PNGase treatment.
Protein lysate preparation with PNGase treatment was carried
out in order to reduce the heterogeneity of the PrP
C bands
resulting from protein-bound Asn-linked oligosaccharides.
Incubation for 30 min on ice was followed by protein reduction,
performed by adding 1% 2-mercaptoethanol and incubating at
90uC for 5 min. After snap cooling on ice, 2 units of PNGase F
(Roche Diagnostics) were added and digestion was carried out
overnight at 37uC. Then, we precipitated the proteins with 3
volumes of cooled methanol for 2 hours at 220uC. Following
centrifugation at 20,000 g for 10 min, the dry pellet was
suspended in lysis buffer prior to denaturation with 46 loading
buffer (Invitrogen, 95613 Cergy-Pontoise France) and heated at
95uC for 5 min. Finally, samples were stored at 280uC.
Total protein quantification. For all samples, we quantified
the lysates for total protein by Bicinchoninic Acid Protein Assay
(BCA assay, Sigma, 38297 Saint Quentin Fallavier France), before
freezing, according to the manufacturer’s instructions.
Determination of PrP
C levels
‘‘The Enzyme Immuno Assay (EIA) Kit for the determination of
PrP
C Protein’’ (SpiBio 91741 Massy France) was applied to 10
6
PBMCs, according to the manufacturer’s instructions. Briefly, we
lysed cells by solubilizing them in 65 ml of extraction buffer (10 mM
Tris-HCl pH 4, 100 mM NaCl, 10 mM EDTA, 0.5% IGEPAL,
and 1% Deoxycholic Acid). After spinning at 10,000 g for 5 min.,
the supernatant was denatured by adding 4 M Urea (final
concentration, diluted in Tris-HCl 10 mM pH 7.4)) and heating
at 100uC for 10 min. Then the EIA, based on a double-antibody
sandwich principle, was performed. The micro-well plate was
coated with a monoclonal antibody specific to the prion protein (aa
144–153). The detection antibody, conjugated with acetylcholines-
terase (AchE), recognized the octo-repeat region located in the N-
terminus part of the PrP
C. Readings were performed at 414 nm.
SDS-PAGE and Immunoblotting
Antibodies. Four different mouse antibodies were used to
span large regions of PrP: SAF32 (SpiBio, 91741 Massy, France) -
which recognizes an octa-repeat region located in the N-terminus
part of human PrP (human numbering 79–91), 8G8 (SpiBio) -
directed against an epitope of human PrP residues 95–110, 3F4
(Signet/Proteogenix, 67412 Illkirch France) - specific for an
epitope of human PrP residues 109–112, and an antibody
provided from ascites fluid PRI 917 (J.Grassi, CEA Saclay,
France) - spanning the COOH- terminus region of human PrP
C
(aa: 216–221). Normalization of the expected signals was achieved
using the signal obtained with monoclonal anti -a- tubulin (Sigma).
SDS-PAGE and Immunoblotting. Protein samples (0.5 10
6
cells/lane i.e. 50 mg of total protein) were separated by 12%
NUPAGE gel electrophoresis (Invitrogen) at 150 volts for 90 min.
Proteins were then transferred to nitrocellulosemembranesHybond
(Amersham biosciences, 91400 Orsay, France) for 45 min at
400 mA using the TE 22 transfer unit (Amersham biosciences).
Afterblockingwith5%non-fat milk inPBS-0.05%Tween 20 buffer,
blots were probed with the panel of selected antibodies in the
dilution conditions recommended by the manufacturer.
Immunoreactivity detection was carried out by a secondary anti-
mouse IgG peroxydase-linked antibody, involved in an ECL
reaction (ECL reagent, Amersham biosciences) and visualized on
an ECL film (Amersham biosciences). Results were quantified by
density readings using Sigmagel Analyzer Software (Sigma).
Weprepared fiveproteinsamplesfor eachgenotype, bothwithand
without PNGase F treatment. Samples were then analyzed using
12% SDS-PAGE separation. We normalized the samples, by
migrating lysate obtained from 0.5610
6 cells - a total protein
concentration of 50 mg +/2 10%/lane - and by comparing the
50 kDa signals obtained by anti -a- tubulin antibody blotting (not
shown).
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Statistical analysis was performed by the test of mean
comparison which obeys the Student-Fisher law (from Fisher
and Yates, Statistical tables for biological, agricultural and medical
research, Olivier and Boyd, Edinburgh). This means that the
mean difference is not significant when the calculated absolute t
value is less than 0.05. If the value is greater than 0.05, this
represents a difference between populations.
Results and Discussion
Characterization of the peripheral blood mononuclear
cells
One possible mechanism explaining the relationship between
the M129V polymorphism and disease development, would be
that the polymorphism influences PrP
C expression and processing
critical for prion propagation [4,16,17,35]. We decided to test this
hypothesis on peripheral blood mononuclear cells (PBMCs) for the
following reasons: the controlled and ethical ease of access to
PBMCs from blood donors allowed us to collect enough samples to
perform a robust analysis. Collecting several hundred human
samples is virtually impossible with other tissues. Secondly, as
mentioned before, blood is an important issue in the context of
vCJD and our results could be important to evaluate the relative
risk of PrP
Sc transmission in different blood components. As
PBMCs express the highest level of PrP compared to platelets and
red blood cells the choice seemed evident even if no experimental
data have showed yet that these cells could indeed propagate
prions. In any case, it is not clear how the prion agent reaches the
bloodstream. Theories propose local replication in specific cell
types, like dendritic cells, or secretion from extra- vascular tissues
[40,41]. Finally, we hypothesized that if the M129V polymor-
phism exerted a more general impact on PrP expression, it could
still be observed in the PBMCs.
Quality controls of the isolated cell population indicated
systematic granulocyte contamination (10% to 15%), with an
acceptable variation of 5% between samples. To determine the
129 polymorphism, we used melting curve analysis to show a
specific melting peak for each genotype: 129-M/M homozygous
genotype peaked at 60uC, V/V homozygous at 52uC, whereas M/
V heterozygous gave 2 peaks at 52uC and 60uC. The genotype
distribution of the donor population of the Languedoc region,
France was 42% M/M, 42% M/V and 16% V/V, values that
agree with the German and the Spanish populations (Table 1)
[39,42]. Of note, a previous study on the French population
observed values of 44% M/M, 46,5% M/V and 9,5% V/V) [43].
However, this study used RFLP-PCR (Restriction Fragment
Length Polymorphism-Polymerase Chain Reaction), a procedure
dependent on digestion efficiency.
PrP
C expression studies
Since PrP
Sc generation depends on PrP
C expression [44], we
examined PrP
C expression in each of the three genotype populations.
We first analyzed PrP
C mRNA levels using real-time PCR
amplification and SYBR Green detection for optimal sensitivity.
Samples were quantified using a standard curve composed of 4
concentrations ranging from 2.33610
6 to 2.33610
3 copies/reaction.
This agreed with the linear correlation between concentration and
cycle number (correlation coefficient: 1 and slope at 3.47, indicating
an acceptable PCR yield at 97%). Results from the 50 M/M, 49 M/
V and 19 V/V blood samples showed no significant difference
between the mRNA levels of the three populations (Table2, observed
t-value less than the 0.05 critical t-value). Nevertheless, the coefficient
of variation (CV) indicated a maximum of 4 fold deviation within
each group. In view of the numerous steps involved in this method
and the normal variation (0.5–0.7 log10) in technologies based on the
same number of steps [45], a deviation of around 0.6 log10 within
each group, denoted low physiological variation. The absence of
significant differences in mRNA expression between the three
genotypes could indicate that transcription regulation does not relate
specifically to genotype. On the other hand, gene expression profiling
studies of scrapie-infected brain tissue have identified numerous genes
that do modify mRNA expression. Likewise, expression of proteins
encoded and involved in several pathways (e.g. inflammatory
reaction, proteolysis, protease inhibition, cell grown, stress, immune
responses…) [46–49] was modified. For these reasons, we needed to
confirm our results at the protein level. We determined PrP
C protein
levels by using a commercial EIA kit, whose N- and C-terminal
antibodies detect the full-length protein. As standard curves were
Table 1. M129V polymorphism distribution.
Met/Met
a Met/Val
a Val/Val
a
France
b 42% 42% 16%
Spanish (52) 40% 46% 14%
German (50) 43% 43% 14%
avalues calculated from 50, 50, and 19 samples respectively per genotype.
bLanguedoc region.
doi:10.1371/journal.pone.0005796.t001
Table 2. PrP
C expression and processing depending on the M129V polymorphism.
PrP
C mRNA
c PrP
Cd PrP
C glycosylation
a PrP
C cleavage
b PrP
C cleavage
b
(copies/2000 cells) (Absorbance Unit) diglyc./unglyc.
e F.L./C2
f C1/C2
g
Met/Met 3.63E+05 1.81 8.86 (SAF 32);3.56 (PRI 917);1.72 (8G8) 6.39 (8G8);3.53(3F4) 2.99 (PRI 917)
Met/Val 4.06E+05 2.02 7.25 (SAF 32);3.65 (PRI 917);1.83 (8G8) 7.50 (8G8);2.71(3F4) 2.20 (PRI 917)
Val/Val 4.98E+05 2.15 8.87 (SAF 32);3.56 (PRI 917);2.09 (8G8) 6.91 (8G8);2.22(3F4) 2.18 (PRI 917)
a13%,VC,47%.
b3%,VC,60%.
c52%,VC,63%.
d15%,VC,20%.
eratio diglycosylated PrP
C/unglycosylated PrP
C calculated by image analysis of the western blot assay performed with SAF 32, PRI 917 and 8G8 antibodies.
fratio full length unglycosylated PrP
C/C2 fragment calculated by image analysis of the western blot assay performed with 8G8 and 3F4 antibodies.
gratio C1 fragment/C2 fragment calculated by image analysis of the western blot assay performed with PRI 917 antibody.
doi:10.1371/journal.pone.0005796.t002
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bency Unit (AU) for each group. Results obtained from 10 blood
samples from each group revealed no statistical difference (observed t-
value less than the 0.05 critical t-values) in total PrP
C levels between
the groups (Table 2). Patients with CJD - and other neurodegener-
ative diseases - show increased PrP
C expression in plasma compared
to healthy control groups [50]. Our findings suggest that such over-
expression in plasma does not result from PBMCs. Nor does it seem
to be linked with M129V polymorphism. Moreover, our total PrP
C
analysisconflictedwiththoseobtainedinsheep,wherePBMCsurface
PrP
C expression did depend upon the genotype. Researchers found
the highest levels of PrP
C in scrapie-susceptible VRQ/VRQ sheep,
and the lowest levels in scrapie-resistant ARR/ARR genotypes [51].
PrP
C glycosylation studies
The PrP protein encounters various post-translational modifi-
cations, including truncation of signalling peptides, GPI anchor-
ing, disulfide bond formation, N-glycosylation, and a- and b-
physiological cleavage. PrP
C is normally glycosylated at positions
182 and 198 and different paradigms show that glycans modulate
the conversion of PrP
C into PrP
Sc [16,17]. For this reason, we
investigated potential differences in PrP
C glycosylation between
the three genotypes by performing Western Blots (WB) before and
after PrP
C deglycosylation with PNGase. Before deglycosylation,
both SAF32 (aa: 78–91) and 3F4 (aa: 109–112) revealed similar
PrP patterns, composed of three bands (Fig. 1): a dominant 35–
37 kDa band corresponding to the diglycosylated full-length PrP
C,
and two faint bands at 29–30 kDa and 27–28 kDa, corresponding
to the monoglycosylated and unglycosylated PrP
C isoforms
respectively [17]. 8G8 antibody recognized two major bands-
corresponding to diglycosylated and unglycosylated PrP
C - and
also a faint band corresponding to the monoglycosylated form (aa:
95–110) (Fig. 1). The C-terminal antibody Pri 917 (aa: 216–221)
showed a major diglycosylated band, and two faint bands
corresponding to monoglycosylated and unglycosylated ptoteins
(Fig. 1).The a-tubuline signal intensity of the samples agrees with
the normalization realized by using 0.5X10
6 cells per lane
corresponding to 50 mg of total protein.
In addition, we observed on blot Pri917 a prominent band
between the unglycosylated and monoglycosylated bands. We
identified this band as non-specific, firstly because the Pri 917 (aa:
216–221) antibody is not purified but an ascitic fluid extract, and
secondly because this band is not present in the 3F4 (aa: 109–112)
and 8G8 blots (aa: 95–110). Finally, we recently ran a blot on
PBMCs using the 12F10 (aa: 142–160), antibody which identified
both C1 and C2 fragments. No non-specific band was detected
(results not shown)
We calculated the ratio between diglycosylated (35–37 kDa) and
unglycosylated (27–28 kDa) isoforms for each sample, after
quantifying SAF32 blot bands using the Sigmagel analyzer
Software. We performed ratio calculations on the SAF32 blot,
because we observed better resolution of low density bands with
this antibody. Comparing the averages of the three ratios, from
five samples of each genotype, showed no significant difference in
expression (observed t-value less than the 0.05 critical t-value)
between the groups (Table 2). These findings were confirmed by
quantifying the Pri 917 (C-terminus region) and 8G8 blots (middle
region among 3F4). Nevertheless, the absolute ratio values differed
according to the antibody used (Table 2).
PrP
C cleavage studies
In the normal brain, PrP
C proteolysis generates an N-terminal
truncated protein - the C1 fragment - from a-cleavage at position
111/112 [18,52]. However, b-cleavage at residue 90 can generate
[52] an additional, longer C-terminal protein – the C2 fragment -
that accumulates in prion-infected brain [4]. Importantly, C2
fragments correspond to protease-resistant and insoluble PrP
Sc.
We therefore investigated potential differences in PrP cleavage
that might affect PrP
Sc generation. Following deglycosylation, we
noticed identical patterns with the different anti-PrP antibodies
between the three genotypes. SAF32 (aa: 78–91) recognized a
major band at 27–28 kDa, which corresponds to the estimated
MW of the unglycosylated full-length PrP
C [52]. As expected, with
this N-terminal antibody, no truncated C-terminal forms could be
identified (Fig. 2). Both 3F4 and 8G8 antibodies, whose epitopes
are located between the a and b cleavage sites, demonstrated
similar patterns: a major 27–28 kDa unglycosylated full-length
protein band and a faint band near 20 kDa corresponding to the
MW of the C2 NH2-terminal truncated fragment of PrP
C
protein(Fig. 2). This confirms previous results [52] As expected,
only the C-terminal antibody Pri 917 (aa: 216–221) identified both
the C1 and C2 truncated proteins [52], at approximately 18 kDa
Figure 1. Analysis of PrPC glycosylation. Immunoblots of PrP
C
glycoforms from the three PRNP codon 129 genotypes in PBMCs.
Denatured lysates from 10
6 PBMCs were tested by Western Blot analysis
using 4 antibodies to span the large PrP region: SAF32 (79–91), 8G8
(95–110), 3F4 (109–112) and PRI 917 (216–221). The 35–37 kDa band
corresponds to the M.W. of the diglycosylated protein (D), while the 29–
30 kDa and 27–28 kDa bands correspond to the M.W. of the
monoglycosylated (M) and unglycosylated (U) proteins respectively. *:
Non-specific signal.
doi:10.1371/journal.pone.0005796.g001
Codon 129 Genotypes and Blood
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e5796and 20 kDa respectively. It also identified the major, unglycosy-
lated full-length protein (27–28 kDa) (Fig. 2).
We calculated the ratio of the unglycosylated full-length PrP
C
(27–28 kDa) to the C2 NH2-terminal truncated protein for each
genotype. Even though the absolute ratios from the 8G8 and 3F4
blots were slightly different, we found no significant difference
between the M/M, M/V and V/V populations (five samples per
genotype) (observed t-value less than 0.05) for C2 expression
(Table 2). As Pri 917 antibody recognizes both C1 and C2
fragments, we also compared the C1/C2 ratios. Values for the M/
M, M/V and V/V populations (five samples per genotype) showed
no significant difference in expression (t-value less than 0.05) with a
good coefficient of variation (Table 2).
Comparative study with human brain tissue (Fig. 3)
We observed two differences when examining normal human
brain with the same antibodies (SAF32 and 3F4). First, brain tissue
showed higher levels of monoglycosylated and unglycosylated
isoforms (Blots SAF 32 and 3F4, respectively), than PBMCs
(fig. 3A). Secondly, brain tissue showed the C2 fragment after
deglycosylation more strongly than PBMCs (fig. 3B). As the
antibodies recognize the same epitope, we cannot explain
variations in expression by differences in antibody affinity. These
findings agree with previous studies [18,52]. Our results suggest
that both the C2 fragment and under- glycosylated PrP
C are
under-expressed in PBMCs in comparison to brain tissue. This
may result from different physiological functions or protein
processing and may influence prion propagation in these tissues.
We suggest that low levels of under-glycosylated isoforms and C2
fragments in PBMCs, compared to normal human brain, explains
the lower blood levels of PrP
Sc measured when contamination
does occur [53,54].
So, the molecular mechanism explaining the relationship
between the PrP M129V genotype and disease development
remains elusive. Although studies have identified some specific
amino-acid interactions for the methionine genotype in vitro [55],
NMR analysis indicated no PrP
C instability related to M129V
polymorphism that could explain disease susceptibility [56]. On
the other hand, a recent study using molecular dynamic
technology demonstrated a higher stability in methionine variants
than valine variants [57]. In addition, a comparison of the
misfolding pathway, leading to the formation of oligomeric
isoforms rich in b-sheets, revealed that methionine 129 human
prion protein oligomerized more rapidly than the valine 129
variant [56]. In patients with iatrogenic CJD from contaminated
human growth hormone, M129V polymorphism also influences
outcome. In this case, homozygous M/M and V/V patients had a
shorter incubation period than the heterozygous patients [58,59].
Figure 2. PrPC cleavage analysis. Immunoblots of truncated
proteins from the three PRNP codon 129 genotypes in PBMCs. After
PNGase treatment, denatured lysates from 10
6 PBMCs were tested by
Western Blot analysis using 4 antibodies to span the large PrP region:
SAF32 (79–91), 8G8 (95–110), 3F4 (109–112) and PRI 917 (216–221). The
27–28 kDa band corresponds to the M.W. of the unglycosylated Full-
Length (F.L.) protein, while the bands near 20 kDa and 18 kDa
correspond to the C2 and C1 fragments, respectively.
doi:10.1371/journal.pone.0005796.g002
Figure 3. Comparative biochemical analysis between brain and
PBMCs. A) Immunoblots of PrP
C glycoforms from PBMCs and brain,
Denatured lysates from 10
6 PBMCs and 10% brain were tested by
Western Blot analysis using 2 antibodies: SAF32 (79–91), 3F4 (109–112).
The 35–37 kDa band corresponds to the M.W. of the diglycosylated
protein (D), while the 29–30 kDa and 27–28 kDa bands correspond to
the M.W. of the monoglycosylated (M) and the unglycosylated (U)
proteins, respectively. B) Immunoblots of truncated proteins from
PBMCs and brain, After PNGase treatment, denatured lysates from 10
6
PBMCs and brain were tested by Western Blot analysis using 3F4 (109–
112). The 27–28 kDa bands correspond to the M.W. of the unglycosy-
lated Full-Length (F.L.) protein while the band near 20 kDa corresponds
to the C2 fragment.
doi:10.1371/journal.pone.0005796.g003
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PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e5796Taken together, our data suggest that in PBMCs, M129V PrP
polymorphism has no significant effect on either PrP mRNA or
protein expression. Neither processing nor apparent PrP glyco-
form distribution seem affected by this M129V polymorphism,
which suggests that we should investigate its relationship with
prion propagation elsewhere.
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